Lipocine Inc.
Lipocine Inc. is a biopharmaceutical company developing drugs for CNS disorders. Its lead product is TLANDO, an oral testosterone replacement therapy. Pipeline candidates include TLANDO XR, LPCN 1148, LPCN 1154, LPCN 2101, and LPCN 2203. The company also developed LPCN 1144, which completed Phase 2 testing, and LPCN 1107, currently in Phase 3 studies for recurrent preterm birth prevention. Founded in 1997, the company is headquartered in Utah.
Overview
Strengths
- Price to book ratio (0.81) is lower than the sector mean (24.44).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (2036.21) is significantly higher than the sector mean (91.15).
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (2.81) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 2036.2 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 2.8 |